scholarly journals NLRP3 Influences Cognitive Function in Schizophrenia in Han Chinese

2021 ◽  
Vol 12 ◽  
Author(s):  
Ruimei Liu ◽  
Wei Tang ◽  
Weiping Wang ◽  
Feikang Xu ◽  
Weixing Fan ◽  
...  
Keyword(s):  
Cascade Reactions ◽  
First Episode ◽  
Eqtl Analysis ◽  
Mrna Levels ◽  
Healthy Controls ◽  
Pyrin Domain ◽  
Genotype Frequencies ◽  
Significant Difference ◽  
Drug Naïve ◽  
First Episode Schizophrenia

It has been proposed that immune abnormalities may be implicated with pathophysiology of schizophrenia. The nod-like receptor pyrin domain-contraining protein 3 (NLRP3) can trigger immune-inflammatory cascade reactions. In this study, we intended to identify the role of gene encoding NLRP3 (NLRP3) in susceptibility to schizophrenia and its clinical features. For the NLRP3 mRNA expression analysis, 53 drug-naïve patients with first-episode schizophrenia and 56 healthy controls were enrolled. For the genetic study, a total of 823 schizophrenia patients and 859 controls were recruited. Among them, 239 drug-naïve patients with first-episode schizophrenia were enrolled for clinical evaluation. There is no significant difference in NLRP3 mRNA levels between patients with schizophrenia and healthy controls (p = 0.07). We did not observe any significant differences in allele and genotype frequencies of rs10754558 polymorphism between the schizophrenia and control groups. We noticed significant differences in the scores of RBANS attention and total scores between the patients with different genotypes of rs10754558 polymorphism (p = 0.001 and p < 0.01, respectively). Further eQTL analysis presented a significant association between the rs10754558 polymorphism and NLRP3 in frontal cortex (p = 0.0028, p = 0.028 after Bonferroni correction). Although our findings did not support NLRP3 confer susceptibility to schizophrenia, NLRP3 may be a risk factor for cognitive impairment, especially attention deficit in this disorder.

scholarly journals The Role of Butyric Acid in Treatment Response in Drug-Naïve First Episode Schizophrenia

2021 ◽  
Vol 12 ◽  
Author(s):  
Xue Li ◽  
Xiaoduo Fan ◽  
Xiuxia Yuan ◽  
Lijuan Pang ◽  
Shaohua Hu ◽  
...  
Keyword(s):  
Treatment Response ◽  
Butyric Acid ◽  
Serum Levels ◽  
First Episode ◽  
Healthy Controls ◽  
Significant Difference ◽  
Drug Naïve ◽  
First Episode Schizophrenia ◽  
Risperidone Treatment

Background: Butyric acid, a major short-chain fatty acid (SCFA), has an important role in the microbiota–gut–brain axis and brain function. This study investigated the role of butyric acid in treatment response in drug-naïve first episode schizophrenia.Methods: The study recruited 56 Chinese Han schizophrenia inpatients with normal body weight and 35 healthy controls. Serum levels of butyric acid were measured using Gas Chromatography-Mass Spectrometer (GC-MS) analysis at baseline (for all participants) and 24 weeks after risperidone treatment (for patients). Clinical symptoms were measured using the Positive and Negative Syndrome Scale (PANSS) for patients at both time points.Results: At baseline, there was no significant difference in serum levels of butyric acid between patients and healthy controls (p = 0.206). However, there was a significant increase in serum levels of butyric acid in schizophrenia patients after 24-week risperidone treatment (p = 0.030). The PANSS total and subscale scores were decreased significantly after 24-week risperidone treatment (p's < 0.001). There were positive associations between baseline serum levels of butyric acid and the reduction ratio of the PANSS total and subscale scores after controlling for age, sex, education, and duration of illness (p's < 0.05). Further, there was a positive association between the increase in serum levels of butyric acid and the reduction of the PANSS positive symptoms subscale scores (r = 0.38, p = 0.019) after controlling for potential confounding factors.Conclusions: Increased serum levels of butyric acid might be associated with a favorable treatment response in drug-naïve, first episode schizophrenia. The clinical implications of our findings were discussed.

scholarly journals Abnormalities of EEG Microstates In Drug-Naïve, First-Episode Schizophrenia

2021 ◽  
Author(s):  
Qiaoling Sun ◽  
Linlin Zhao ◽  
Liwen Tan
Keyword(s):  
Clinical Symptoms ◽  
Early Stage ◽  
First Episode ◽  
Healthy Controls ◽  
Brain Functions ◽  
Class D ◽  
Syndrome Scale ◽  
Drug Naïve ◽  
Microstate Analysis ◽  
First Episode Schizophrenia

Abstract Objective: Microstate analysis is a powerful tool to probe the brain functions, and changes in microstates under electroencephalography (EEG) have been repeatedly reported in patients with schizophrenia. This study aimed to investigate the dynamics of EEG microstates in drug-naïve, first-episode schizophrenia (FE-SCH) and to test the relationship between EEG microstates and clinical symptoms.Methods: Resting-state EEG were recorded for 23 patients with FE-SCH and 23 healthy controls using a 64-channel cap. Three parameters, i.e., contribution, duration, and occurrence, of the four microstate classes were calculated. Group differences in EEG microstates and their clinical symptoms (assessed using the Positive and Negative Syndrome Scale) were analyzed.Results: Compared with healthy controls, patients with FE-SCH showed increased duration, occurrence and contribution of microstate class C and decreased contribution and occurrence of microstate class D. In addition, the score of positive symptoms in PANSS was negatively correlated with the occurrence of microstate D.Conclusions: Our findings showed abnormal patterns of EEG microstates in drug-naïve, first-episode schizophrenia, which might help distinguish individuals with schizophrenia in the early stage and develop early intervention strategies.

The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls

2013 ◽  
Vol 150 (1) ◽  
pp. 157-162 ◽  
Author(s):  
Xiaoli Wu ◽  
Zeping Huang ◽  
Renrong Wu ◽  
Zhiyong Zhong ◽  
Qinling Wei ◽  
...  
Keyword(s):  
Lipid Profiles ◽  
First Episode ◽  
Healthy Controls ◽  
Drug Naïve ◽  
First Episode Schizophrenia

scholarly journals Reducedγ-Aminobutyric Acid and Glutamate+Glutamine Levels in Drug-Naïve Patients with First-Episode Schizophrenia but Not in Those at Ultrahigh Risk

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Junjie Wang ◽  
Yingying Tang ◽  
Tianhong Zhang ◽  
Huiru Cui ◽  
Lihua Xu ◽  
...  
Keyword(s):  
Prefrontal Cortex ◽  
Proton Magnetic Resonance ◽  
Proton Magnetic Resonance Spectroscopy ◽  
Aminobutyric Acid ◽  
First Episode ◽  
Resonance Spectroscopy ◽  
Healthy Controls ◽  
Drug Naïve ◽  
First Episode Schizophrenia

Alteredγ-aminobutyric acid (GABA), glutamate (Glu) levels, and an imbalance between GABAergic and glutamatergic neurotransmissions have been involved in the pathophysiology of schizophrenia. However, it remains unclear how these abnormalities impact the onset and course of psychosis. In the present study, 21 drug-naïve subjects at ultrahigh risk for psychosis (UHR), 16 drug-naïve patients with first-episode schizophrenia (FES), and 23 healthy controls (HC) were enrolled. In vivo GABA and glutamate+glutamine (Glx) levels in the medial prefrontal cortex were measured using proton magnetic resonance spectroscopy. Medial prefrontal GABA and Glx levels in FES patients were significantly lower than those in HC and UHR, respectively. GABA and Glx levels in UHR were comparable with those in HC. In each group, there was a positive correlation between GABA and Glx levels. Reduced medial prefrontal GABA and Glx levels thus may play an important role in the early stages of schizophrenia.

Effects of quetiapine in first episode schizophrenia. Comparison with drug naive patients and healthy controls

2003 ◽  
Vol 60 (1) ◽  
pp. 224-225
Author(s):  
H.M. Jones ◽  
M.J. Brammer ◽  
R. Ohlsen ◽  
M. O'Toole ◽  
T. Taylor ◽  
...  
Keyword(s):  
First Episode ◽  
Healthy Controls ◽  
Drug Naïve ◽  
First Episode Schizophrenia

Neuroimaging-based brain-age prediction of first-episode schizophrenia and the alteration of brain age after early medication

2021 ◽  
pp. 1-8
Author(s):  
Yi-Bin Xi ◽  
Xu-Sha Wu ◽  
Long-Biao Cui ◽  
Li-Jun Bai ◽  
Shuo-Qiu Gan ◽  
...  
Keyword(s):  
Diffusion Tensor ◽  
First Episode ◽  
Age Difference ◽  
Healthy Controls ◽  
Data Set ◽  
Brain Ageing ◽  
First Episode Schizophrenia ◽  
Brain Age ◽  
The Brain ◽  
Age Prediction

Background Neuroimaging- and machine-learning-based brain-age prediction of schizophrenia is well established. However, the diagnostic significance and the effect of early medication on first-episode schizophrenia remains unclear. Aims To explore whether predicted brain age can be used as a biomarker for schizophrenia diagnosis, and the relationship between clinical characteristics and brain-predicted age difference (PAD), and the effects of early medication on predicted brain age. Method The predicted model was built on 523 diffusion tensor imaging magnetic resonance imaging scans from healthy controls. First, the brain-PAD of 60 patients with first-episode schizophrenia, 60 healthy controls and 21 follow-up patients from the principal data-set and 40 pairs of individuals in the replication data-set were calculated. Next, the brain-PAD between groups were compared and the correlations between brain-PAD and clinical measurements were analysed. Results The patients showed a significant increase in brain-PAD compared with healthy controls. After early medication, the brain-PAD of patients decreased significantly compared with baseline (P < 0.001). The fractional anisotropy value of 31/33 white matter tract features, which related to the brain-PAD scores, had significantly statistical differences before and after measurements (P < 0.05, false discovery rate corrected). Correlation analysis showed that the age gap was negatively associated with the positive score on the Positive and Negative Syndrome Scale in the principal data-set (r = −0.326, P = 0.014). Conclusions The brain age of patients with first-episode schizophrenia may be older than their chronological age. Early medication holds promise for improving the patient's brain ageing. Neuroimaging-based brain-age prediction can provide novel insights into the understanding of schizophrenia.

Sign in / Sign up

Export Citation Format

Share Document